GlassScriptPhysician profile
Galena Salem
NPI 1538334420
$8,175.68
in general payments reported to CMS, 2019-2025
53 companies · $811 in 2025
The $811 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,802 · 2020: $411 · 2021: $637 · 2022: $1,477 · 2023: $1,832 · 2024: $1,206 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,738 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,738.13 |
| Education | $110.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,021.17 | 2019-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $863.97 | 2019-2025 | |
| Celgene Corporation | $778.99 | 2019-2025 | Reblozyl, Opdualag, Opdivo |
| Merck Sharp & Dohme LLC | $615.12 | 2019-2025 | Keytruda, Lynparza |
| Amgen INC. | $576.41 | 2019-2023 | Lumakras, Blincyto |
| Pfizer INC. | $515.35 | 2019-2025 | |
| Daiichi Sankyo INC. | $460.48 | 2019-2025 | Enhertu, Injectafer |
| Astellas Pharma US INC | $399.03 | 2019-2024 | Padcev |
| Janssen Biotech, INC. | $361.07 | 2019-2025 | Darzalex, Tecvayli, Imbruvica |
| Seagen INC. | $293.37 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Genentech USA, INC. | $193.96 | 2019-2023 | Venclexta |
| Gilead Sciences, INC. | $190.84 | 2019-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $149.86 | 2019-2023 | |
| Incyte Corporation | $140.58 | 2021-2024 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $136.24 | 2019-2024 | Lynparza |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Galena Salem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.